
|Videos|December 21, 2022
Importance of Biomarker Testing in Patients with NSCLC
Author(s)Mark Socinski, MD, Joshua K. Sabari, MD
Two experts discuss the evolving treatment landscape for patients with non-small cell lung cancer (NSCLC) and reviews the role of molecular testing and discusses some of the challenges faced.
Advertisement
Episodes in this series

Now Playing
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Daratumumab Quadruplet for Transplant-Ineligible Myeloma
2
Atebimetinib Combo Shows Compelling 1-Year OS in First-Line Pancreatic Cancer
3
FDA Grants Fast Track Designation to IBI3003 for R/R Multiple Myeloma
4
Tafasitamab Combo Significantly Extends PFS in R/R Follicular Lymphoma
5



















